Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk).

Winters MP, Robinson DJ, Khine HH, Pullen SS, Woska JR Jr, Raymond EL, Sellati R, Cywin CL, Snow RJ, Kashem MA, Wolak JP, King J, Kaplita PV, Liu LH, Farrell TM, DesJarlais R, Roth GP, Takahashi H, Moriarty KJ.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5541-4. doi: 10.1016/j.bmcl.2008.09.016. Epub 2008 Sep 7.

PMID:
18823779
2.

Itk inhibitors: a patent review.

Lo HY.

Expert Opin Ther Pat. 2010 Apr;20(4):459-69. doi: 10.1517/13543771003674409. Review.

PMID:
20218931
3.

The therapeutic journey of benzimidazoles: a review.

Bansal Y, Silakari O.

Bioorg Med Chem. 2012 Nov 1;20(21):6208-36. doi: 10.1016/j.bmc.2012.09.013. Epub 2012 Sep 17. Review.

PMID:
23031649
4.

Benzimidazoles: an ideal privileged drug scaffold for the design of multitargeted anti-inflammatory ligands.

Kaur G, Kaur M, Silakari O.

Mini Rev Med Chem. 2014;14(9):747-67. Review.

PMID:
25138088
5.

Therapeutic evolution of benzimidazole derivatives in the last quinquennial period.

Akhtar W, Khan MF, Verma G, Shaquiquzzaman M, Rizvi MA, Mehdi SH, Akhter M, Alam MM.

Eur J Med Chem. 2017 Jan 27;126:705-753. doi: 10.1016/j.ejmech.2016.12.010. Epub 2016 Dec 5. Review.

PMID:
27951484

Supplemental Content

Support Center